ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1655

Histologic Features Correlate with the Modified Rodnan Skin Score, Serum Inflammatory Markers, and Patient Reported Outcomes in Patients with Early, Diffuse Cutaneous Systemic Sclerosis

Kimberly Showalter1, Cynthia Magro 2, Dana Orange 3, Yaxia Zhang 4, Phaedra Agius 5, Jackie Finik 6, Robert Spiera 1 and Jessica Gordon 1, 1Hospital for Special Surgery, New York, NY, 2Weill Cornell Medicine, New York, 3Rockefeller University, New York, 4Hospital for Special Surgery, New York, 5New York Genome Center, New York City, 6Hospital for Special Surgery, New York, NY, New York, NY

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Autoimmune Skin Disease and Dermatopathology, Outcome measures, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: Systemic Sclerosis & Related Disorders – Clinical Poster II

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The association between systemic sclerosis (SSc) skin histology and clinical findings is not fully characterized. In two SSc trials, we developed a scoring system to evaluate histologic change. The purpose of this study is to determine (1) the reliability of our histology scores and (2) if histologic features correlate with clinical findings.

Methods: Skin biopsies were assessed from patients enrolled in Nilotinib (n=7) and Belimumab (n=18) trials. Our skin histology scoring approach, developed with dermatopatholgist (CM) consultation, includes skin thickness (epidermis to subcutis), follicle count, and semi-quantitative (0-3) assessment of infiltrate, collagen density, alpha-smooth muscle actin (aSMA) and CD34 staining intensity, and global histologic severity. Blinded to prior scores, a dermatopathogist (CM) and second pathologist (YZ), oriented to our approach, analyzed a sub-sample of biopsies. Intraclass correlation coefficients (ICC) were calculated for inter- and intra-rater reliability. Spearman correlations were used to correlate histology scores (baseline, 52-weeks post-treatment, and overall) and clinical variables (local and total modified Rodnan skin score (MRSS), erythrocyte sedimentation rate (ESR), c-reactive protein (CRP), 36-item Short Form Health Survey (SF-36), and physician global assessment (PGA)).

Results: 56 biopsies were analyzed from 26 diffuse SSc patients (median (IQR) disease duration 0.8 (0.54) years). Most were female (77%), Caucasian (73%), and RNA polymerase III positive (58%). Median (IQR) baseline MRSS was 25 (9). Reliability was excellent (ICC≥0.90) for follicle count and intra-rater CD34; good (0.75< ICC >0.90) for thickness, inter-rater CD34, intra-rater collagen density, and intra-rater global score; and moderate (0.5< ICC >0.75) for infiltrate, intra-rater collagen density, aSMA, and inter-rater global score.

Histologic scores correlated moderately with MRSS, ESR, CRP, and SF-36 (Table 1). Post-treatment local MRSS correlated with thickness (r=0.674, p< 0.001), collagen density (r=0.497, p=0.04), global histologic severity (r=0.467, p=0.02), follicle count (r=-0.550, p=0.01), and CD34 stain intensity (r=-0.653, p=0.001). However, local MRSS did not correlate with infiltrate score or PGA and weakly correlated with aSMA stain intensity (r=0.337, p=0.01). In stratified analysis, collagen density correlated with local MRSS in patients with low (< 1) but not high (≥1) infiltrate score (r=0.578, p< 0.001 vs. r=0.253, p=0.256). Total MRSS correlated with collagen density (r=0.425, p=0.001) and CD34 stain intensity (r=-0.460, p< 0.001). Total MRSS and thickness correlated positively in patients with low infiltrate (r=0.326, p=0.05) but negatively in patients with high infiltrate (r=-0.456, p=0.03).

Conclusion: Our scores demonstrate moderate to excellent reliability, thus have potential to be used across centers. Histologic features correlate with MRSS, inflammatory markers, and patient reported outcomes. However, infiltrate does not correlate with MRSS and confounds the correlation of MRSS with collagen density and thickness. This supports further study of skin histology as an SSc outcome measure.


Table1_Histology


Disclosure: K. Showalter, None; C. Magro, None; D. Orange, None; Y. Zhang, None; P. Agius, None; J. Finik, None; R. Spiera, BMS, 2, Boehringer Ingelheim, 2, Bristol-Myers Squibb, 2, ChemoCentryx, 2, 5, Chemocentryx, 2, Corbus, 2, CSL Behring, 5, Cytori, 2, Formation Biologics, 2, Genentech, Inc., 2, Genzyme/Sanofi, 2, 5, GlaxoSmithKline, 2, 5, GSK, 2, 5, Hoffman-La Roche Ltd, 2, Janssen, 5, Mitsubishi, 5, Roche, 2, Roche Genetech, 2, 5, Roche/Genetech, 2, 5, Roche-Genentech, 2, 5, Roche-Genetech, 2, 5, Sanofi, 5, Sanofi-Aventis, 5; J. Gordon, Cumberland, 2, Corbus, 2.

To cite this abstract in AMA style:

Showalter K, Magro C, Orange D, Zhang Y, Agius P, Finik J, Spiera R, Gordon J. Histologic Features Correlate with the Modified Rodnan Skin Score, Serum Inflammatory Markers, and Patient Reported Outcomes in Patients with Early, Diffuse Cutaneous Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/histologic-features-correlate-with-the-modified-rodnan-skin-score-serum-inflammatory-markers-and-patient-reported-outcomes-in-patients-with-early-diffuse-cutaneous-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/histologic-features-correlate-with-the-modified-rodnan-skin-score-serum-inflammatory-markers-and-patient-reported-outcomes-in-patients-with-early-diffuse-cutaneous-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology